WO2022100195A1 - Method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride - Google Patents
Method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride Download PDFInfo
- Publication number
- WO2022100195A1 WO2022100195A1 PCT/CN2021/114067 CN2021114067W WO2022100195A1 WO 2022100195 A1 WO2022100195 A1 WO 2022100195A1 CN 2021114067 W CN2021114067 W CN 2021114067W WO 2022100195 A1 WO2022100195 A1 WO 2022100195A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluoro
- metal
- chloride
- methoxybenzenesulfonyl chloride
- lithium
- Prior art date
Links
- MEOZOFVLIUUROW-UHFFFAOYSA-N 2-fluoro-5-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(F)C(S(Cl)(=O)=O)=C1 MEOZOFVLIUUROW-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 8
- 229910052751 metal Inorganic materials 0.000 claims abstract description 22
- 239000002184 metal Substances 0.000 claims abstract description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- LYIGJBQYDRJPIR-UHFFFAOYSA-N 2-bromo-1-fluoro-4-methoxybenzene Chemical compound COC1=CC=C(F)C(Br)=C1 LYIGJBQYDRJPIR-UHFFFAOYSA-N 0.000 claims abstract description 8
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 125000003118 aryl group Chemical group 0.000 claims abstract description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 10
- -1 alkyl magnesium Chemical compound 0.000 claims description 9
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 20
- 238000009776 industrial production Methods 0.000 abstract description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002390 rotary evaporation Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 108010022404 serum-glucocorticoid regulated kinase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 2
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 description 1
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- BBPAICDPWINHGF-UHFFFAOYSA-N O=S(NC(C=C1)=CC=C1C1=CC=C(C=NN2)C2=C1)=O Chemical compound O=S(NC(C=C1)=CC=C1C1=CC=C(C=NN2)C2=C1)=O BBPAICDPWINHGF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- WXJBZPDYIKQTBZ-UHFFFAOYSA-L [Li+].[Cl-].[Br-].CC(C)[Mg+] Chemical compound [Li+].[Cl-].[Br-].CC(C)[Mg+] WXJBZPDYIKQTBZ-UHFFFAOYSA-L 0.000 description 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- FQYGKMVSWVJCJG-UHFFFAOYSA-N n-[4-(3-amino-2h-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-2-fluoro-5-methoxybenzenesulfonamide Chemical compound COC1=CC=C(F)C(S(=O)(=O)NC=2C=CC(=CC=2)C2=NC3=NNC(N)=C3C=N2)=C1 FQYGKMVSWVJCJG-UHFFFAOYSA-N 0.000 description 1
- KYUKUHICYOEKSV-UHFFFAOYSA-N n-[4-[4-(1-acetylpiperidin-4-yl)oxy-3-methyl-2h-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-2-fluoro-5-methoxybenzenesulfonamide Chemical compound COC1=CC=C(F)C(S(=O)(=O)NC=2C=CC(=CC=2)C2=NC3=NNC(C)=C3C(OC3CCN(CC3)C(C)=O)=N2)=C1 KYUKUHICYOEKSV-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/78—Halides of sulfonic acids
- C07C309/86—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/87—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
Definitions
- the present disclosure belongs to the field of medicinal chemistry, and in particular relates to a method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride.
- 2-Fluoro-5-methoxybenzenesulfonyl chloride (CAS number: 1214334-01-6), whose structure is shown in formula I, is an important intermediate for the synthesis of various new drugs.
- Patent WO2014140065 discloses a new compound, N-(4-(azaindol-6-yl)-phenyl)-sulfonamide, which is a valuable pharmacologically active compound that modulates protein kinase activity, especially Serum and glucocorticoid-regulated kinase (SGK) activity is a potential drug for the treatment of diseases with inappropriate SGK activity, such as degenerative joint diseases or inflammatory processes such as osteoarthritis or rheumatism.
- SGK Serum and glucocorticoid-regulated kinase
- Patent WO2015198045 discloses new compounds, 3-substituted 2-aminoindole derivatives and analogs, which are potential drugs for the treatment or prevention of GPR43 receptor-related disorders, such as diabetes, obesity and inflammatory bowel disease.
- 2-fluoro-5-methoxybenzenesulfonyl chloride is an important raw material for the synthesis of related compounds, and the synthetic route is shown in Scheme 1.
- the purpose of the present disclosure is to provide a preparation method of 2-fluoro-5-methoxybenzenesulfonyl chloride which is easy to operate and easy to industrialize in view of the deficiencies of the prior art.
- X is selected from F, Cl, Br and I; M is selected from Mg, Zn, Li and combinations thereof.
- the operation steps are: using 3-bromo-4-fluoroanisole as raw material, reacting with metal or metal reagent to obtain aryl metal reagent III, and then reacting with sulfonyl chloride to obtain 2-fluoro-5-methoxyl group Benzenesulfonyl chloride.
- the metal or metal reagent is selected from the group consisting of C 1 -C 6 straight or branched alkyl magnesium, C 1 -C 6 straight or branched alkyl magnesium halide, lithium halide, C 1 -C 6 One or a mixture of linear or branched alkyl lithium, metal magnesium, metal zinc, and metal lithium.
- the metal or metal reagent is selected from magnesium metal, C1 - C6 straight or branched alkyl magnesium, C1 - C6 straight or branched alkyl magnesium halide lithium halide.
- the metal reagent is selected from the group consisting of isopropylmagnesium chloride lithium chloride, isopropylmagnesium bromide lithium chloride, isopropylmagnesium chloride, isopropylmagnesium bromide, preferably isopropylmagnesium chloride lithium chloride .
- the beneficial effect of the present disclosure is that the present disclosure provides a new and unreported preparation method of 2-fluoro-5-methoxybenzenesulfonyl chloride, using 3-bromo-4-fluoroanisole as a raw material,
- the reaction steps are short, the operation is simple, the reaction conditions are mild, and the method is suitable for industrial production.
- the tetrahydrofuran was removed by rotary evaporation, extracted with dichloromethane, washed with water, and rotary evaporation was performed to obtain a brown liquid, and oil pump distillation was used to obtain 4.2 g of a colorless liquid.
- the 1 H NMR chart is shown in FIG. 1 .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present disclosure provides a method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride. 3-bromo-4-fluoroanisole is used as a raw material and reacts with a metal or metal reagent to obtain an aryl metal reagent, which then reacts with sulfonyl chloride to obtain 2-fluoro-5-methoxybenzenesulfonyl chloride. The method provided by the present disclosure has short reaction steps, simple operation and mild reaction conditions, and is suitable for industrial production.
Description
相关申请的交叉引用CROSS-REFERENCE TO RELATED APPLICATIONS
本公开要求于2020年11月16日提交中国专利局的申请号为202011278152.X、名称为“一种制备2-氟-5-甲氧基苯磺酰氯的方法”的中国专利申请的优先权,其全部内容通过引用结合在本公开中。This disclosure claims the priority of the Chinese patent application entitled "A Method for Preparing 2-Fluoro-5-Methoxybenzenesulfonyl Chloride" with application number 202011278152.X filed with the China Patent Office on November 16, 2020 , the entire contents of which are incorporated by reference in this disclosure.
本公开属于药物化学领域,具体涉及一种制备2-氟-5-甲氧基苯磺酰氯的方法。The present disclosure belongs to the field of medicinal chemistry, and in particular relates to a method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride.
2-氟-5-甲氧基苯磺酰氯(CAS号:1214334-01-6),结构如式I所示,是合成多种新药的重要中间体。2-Fluoro-5-methoxybenzenesulfonyl chloride (CAS number: 1214334-01-6), whose structure is shown in formula I, is an important intermediate for the synthesis of various new drugs.
专利WO2014140065中公开一种新的化合物,N-(4-(氮杂吲哚-6-基)-苯基)-磺酰胺是有价值的药理学活性的化合物,其调节蛋白激酶活性,特别是血清和糖皮质激素调节激酶(SGK)的活性,是潜在的用于治疗SGK活性不适当疾病的药物,例如退化性关节疾病或炎性过程诸如骨关节炎或风湿病。其中,N-[4-(3-氨基-4-异丁氧基-1H-吡唑并[3,4-d]嘧啶-6-基)-苯基]-2-氟-5-甲氧基-苯磺酰胺;N-[4-(3-氨基-1H-吡唑并[3,4-d]嘧啶-6-基)-苯基]-2-氟-5-甲氧基-苯磺酰胺;N-{4-[4-(1-乙酰基-哌啶-4-基氧基)-3-甲基-1H-吡唑并[3,4-d]嘧啶-6-基]-苯基}-2-氟-5-甲氧基-苯磺酰胺等都是由2-氟-5-甲氧基苯磺酰氯作为原料制备而来。Patent WO2014140065 discloses a new compound, N-(4-(azaindol-6-yl)-phenyl)-sulfonamide, which is a valuable pharmacologically active compound that modulates protein kinase activity, especially Serum and glucocorticoid-regulated kinase (SGK) activity is a potential drug for the treatment of diseases with inappropriate SGK activity, such as degenerative joint diseases or inflammatory processes such as osteoarthritis or rheumatism. Wherein, N-[4-(3-amino-4-isobutoxy-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-phenyl]-2-fluoro-5-methoxy yl-benzenesulfonamide; N-[4-(3-Amino-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-phenyl]-2-fluoro-5-methoxy-benzene Sulfonamide; N-{4-[4-(1-Acetyl-piperidin-4-yloxy)-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl] -Phenyl}-2-fluoro-5-methoxy-benzenesulfonamide, etc. are all prepared from 2-fluoro-5-methoxybenzenesulfonyl chloride as a raw material.
专利WO2015198045中公开新化合物3-取代的2-胺基吲哚衍生物及类似物,其是潜在的治疗或预防与GPR43受体有关病症的药物,如糖尿病、肥胖症和炎症性肠病。其中,2-氟-5-甲氧基苯磺酰氯是合成相关化合物的重要原料,合成路线如Scheme 1所示。Patent WO2015198045 discloses new compounds, 3-substituted 2-aminoindole derivatives and analogs, which are potential drugs for the treatment or prevention of GPR43 receptor-related disorders, such as diabetes, obesity and inflammatory bowel disease. Among them, 2-fluoro-5-methoxybenzenesulfonyl chloride is an important raw material for the synthesis of related compounds, and the synthetic route is shown in Scheme 1.
目前,并无现有技术公开报道2-氟-5-甲氧基苯磺酰氯的制备方法。At present, there is no prior art publicly reporting the preparation method of 2-fluoro-5-methoxybenzenesulfonyl chloride.
发明内容SUMMARY OF THE INVENTION
本公开的目的在于针对现有技术的不足,提供一种操作简单易于产业化的2-氟-5-甲氧基苯磺酰氯的制备方法。The purpose of the present disclosure is to provide a preparation method of 2-fluoro-5-methoxybenzenesulfonyl chloride which is easy to operate and easy to industrialize in view of the deficiencies of the prior art.
本公开采用的技术方案如下:The technical scheme adopted in the present disclosure is as follows:
其中,X选自F、Cl、Br和I;M选自Mg、Zn、Li及其组合。Wherein, X is selected from F, Cl, Br and I; M is selected from Mg, Zn, Li and combinations thereof.
操作步骤为:以3-溴-4-氟苯甲醚为原料,经与金属或金属试剂发生反应制得芳基金属试剂III,再与磺酰氯反应制得2-氟-5-甲氧基苯磺酰氯。The operation steps are: using 3-bromo-4-fluoroanisole as raw material, reacting with metal or metal reagent to obtain aryl metal reagent III, and then reacting with sulfonyl chloride to obtain 2-fluoro-5-methoxyl group Benzenesulfonyl chloride.
在一些实施方式中,所述金属或金属试剂选自C
1-C
6直链或支链烷基镁、C
1-C
6直链或支链烷基卤化镁卤化锂、C
1-C
6直链或支链烷基锂、金属镁、金属 锌、金属锂中的一种或几种的混合物。
In some embodiments, the metal or metal reagent is selected from the group consisting of C 1 -C 6 straight or branched alkyl magnesium, C 1 -C 6 straight or branched alkyl magnesium halide, lithium halide, C 1 -C 6 One or a mixture of linear or branched alkyl lithium, metal magnesium, metal zinc, and metal lithium.
在一些实施方式中,所述金属或金属试剂选自金属镁、C
1-C
6直链或支链烷基镁、C
1-C
6直链或支链烷基卤化镁卤化锂。
In some embodiments, the metal or metal reagent is selected from magnesium metal, C1 - C6 straight or branched alkyl magnesium, C1 - C6 straight or branched alkyl magnesium halide lithium halide.
在一些实施方式中,所述金属试剂选自异丙基氯化镁氯化锂、异丙基溴化镁氯化锂、异丙基氯化镁、异丙基溴化镁,优选异丙基氯化镁氯化锂。In some embodiments, the metal reagent is selected from the group consisting of isopropylmagnesium chloride lithium chloride, isopropylmagnesium bromide lithium chloride, isopropylmagnesium chloride, isopropylmagnesium bromide, preferably isopropylmagnesium chloride lithium chloride .
本公开的有益效果在于,本公开提供了一种新的未见报道过的2-氟-5-甲氧基苯磺酰氯的制备方法,选用3-溴-4-氟苯甲醚为原料,反应步骤简短,操作简单,反应条件温和,适合于工业化生产。The beneficial effect of the present disclosure is that the present disclosure provides a new and unreported preparation method of 2-fluoro-5-methoxybenzenesulfonyl chloride, using 3-bromo-4-fluoroanisole as a raw material, The reaction steps are short, the operation is simple, the reaction conditions are mild, and the method is suitable for industrial production.
图1实施例1中2-氟-5-甲氧基苯磺酰氯的
1HNMR图
Figure 11 HNMR chart of 2-fluoro-5-methoxybenzenesulfonyl chloride in Example 1
下面结合实施例对本公开的技术内容作进一步的阐述,其目的是为了更好的理解本公开的内容,但本公开的保护范围不限于此。The technical content of the present disclosure will be further elaborated below in conjunction with the embodiments, the purpose of which is to better understand the content of the present disclosure, but the protection scope of the present disclosure is not limited thereto.
实施例1 2-氟-5-甲氧基苯磺酰氯的制备Example 1 Preparation of 2-fluoro-5-methoxybenzenesulfonyl chloride
将35mL异丙基氯化镁氯化锂加入50mL三颈瓶中,0℃下,加入6.0g 3-溴-4-氟苯甲醚搅拌反应1小时。将反应液降温至-30℃,并向其中加入溶于四氢呋喃中的磺酰氯,继续反应0.5小时,反应结束后,加水淬灭,继续搅拌0.5小 时。旋转蒸掉四氢呋喃,用二氯甲烷萃取,水洗,旋转蒸发得到棕色液体,油泵蒸馏得到无色液体4.2g。
1HNMR图见图1。
35 mL of isopropylmagnesium chloride and lithium chloride were added to a 50 mL three-neck flask, and at 0° C., 6.0 g of 3-bromo-4-fluoroanisole was added and the reaction was stirred for 1 hour. The reaction solution was cooled to -30°C, sulfonyl chloride dissolved in tetrahydrofuran was added thereto, and the reaction was continued for 0.5 hour. After the reaction was completed, water was added to quench, and stirring was continued for 0.5 hour. The tetrahydrofuran was removed by rotary evaporation, extracted with dichloromethane, washed with water, and rotary evaporation was performed to obtain a brown liquid, and oil pump distillation was used to obtain 4.2 g of a colorless liquid. The 1 H NMR chart is shown in FIG. 1 .
实施例2 2-氟-5-甲氧基苯磺酰氯的制备Example 2 Preparation of 2-fluoro-5-methoxybenzenesulfonyl chloride
将200mL异丙基溴化镁加入500mL三颈瓶中,0℃下,加入60g 3-溴-4-氟苯甲醚搅拌反应1小时。将反应液降温至-30℃,并向其中加入溶于四氢呋喃中的磺酰氯,继续反应0.5小时,反应结束后,加水淬灭,继续搅拌1小时。旋转蒸掉四氢呋喃,用二氯甲烷萃取,水洗,旋转蒸发得到棕色液体,油泵蒸馏得到无色液体38.1g。200 mL of isopropylmagnesium bromide was added to a 500 mL three-neck flask, and 60 g of 3-bromo-4-fluoroanisole was added at 0° C. to stir the reaction for 1 hour. The reaction solution was cooled to -30°C, and sulfonyl chloride dissolved in tetrahydrofuran was added thereto, and the reaction was continued for 0.5 hour. After the reaction was completed, water was added to quench, and stirring was continued for 1 hour. The tetrahydrofuran was removed by rotary evaporation, extracted with dichloromethane, washed with water, and rotary evaporated to obtain a brown liquid, and oil pump distillation to obtain 38.1 g of a colorless liquid.
实施例3 2-氟-5-甲氧基苯磺酰氯的制备Example 3 Preparation of 2-fluoro-5-methoxybenzenesulfonyl chloride
将3g金属锂加入500mL三颈瓶中,0℃下,加入5g 3-溴-4-氟苯甲醚搅拌反应4小时。将反应液降温至-45℃,并向其中加入溶于四氢呋喃中的磺酰氯,继续反应2小时,反应结束后,加水淬灭,继续搅拌1小时。旋转蒸掉四氢呋喃,用二氯甲烷萃取,水洗,旋转蒸发得到棕色液体,油泵蒸馏得到无色液体2.3g。3 g of metallic lithium was added to a 500 mL three-neck flask, and 5 g of 3-bromo-4-fluoroanisole was added at 0°C to stir the reaction for 4 hours. The reaction solution was cooled to -45°C, and sulfonyl chloride dissolved in tetrahydrofuran was added thereto, and the reaction was continued for 2 hours. After the reaction was completed, water was added to quench, and stirring was continued for 1 hour. The tetrahydrofuran was removed by rotary evaporation, extracted with dichloromethane, washed with water, and rotary evaporation was performed to obtain a brown liquid, and oil pump distillation was used to obtain 2.3 g of a colorless liquid.
实施例4 2-氟-5-甲氧基苯磺酰氯的制备Example 4 Preparation of 2-fluoro-5-methoxybenzenesulfonyl chloride
将2g金属锌加入500mL三颈瓶中,0℃下,加入5g 3-溴-4-氟苯甲醚搅拌反应3小时。将反应液降温至-40℃,并向其中加入溶于四氢呋喃中的磺酰氯,继续反应1小时,反应结束后,加水淬灭,继续搅拌1小时。旋转蒸掉四氢呋喃,用二氯甲烷萃取,水洗,旋转蒸发得到棕色液体,油泵蒸馏得到无色液体 1.7g。2g of metallic zinc was added to a 500mL three-neck flask, and at 0°C, 5g of 3-bromo-4-fluoroanisole was added and the reaction was stirred for 3 hours. The reaction solution was cooled to -40°C, and sulfonyl chloride dissolved in tetrahydrofuran was added thereto, and the reaction was continued for 1 hour. After the reaction was completed, water was added to quench, and stirring was continued for 1 hour. The tetrahydrofuran was removed by rotary evaporation, extracted with dichloromethane, washed with water, and rotary evaporation was performed to obtain a brown liquid, and oil pump distillation was used to obtain 1.7 g of a colorless liquid.
Claims (2)
- 一种制备2-氟-5-甲氧基苯磺酰氯的方法,其特征在于,以3-溴-4-氟苯甲醚为原料,与金属或金属试剂发生反应制得芳基金属试剂III,再与磺酰氯反应制得2-氟-5-甲氧基苯磺酰氯;A method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride, characterized in that, using 3-bromo-4-fluoroanisole as a raw material, reacting with metal or metal reagent to obtain aryl metal reagent III , and then react with sulfonyl chloride to obtain 2-fluoro-5-methoxybenzenesulfonyl chloride;具体路线如下:The specific route is as follows:其中,X选自F、Cl、Br和I;M选自Mg、Zn、Li及其组合。Wherein, X is selected from F, Cl, Br and I; M is selected from Mg, Zn, Li and combinations thereof.
- 一种如权利要求1所述的制备方法,其特征在于,所述金属或金属试剂选自C 1-C 6直链或支链烷基镁、C 1-C 6直链或支链烷基卤化镁卤化锂、C 1-C 6直链或支链烷基锂、金属镁、金属锌、金属锂中的一种或几种的混合物。 A preparation method as claimed in claim 1, characterized in that, the metal or metal reagent is selected from C 1 -C 6 straight-chain or branched alkyl magnesium, C 1 -C 6 straight-chain or branched alkyl One or more mixtures of magnesium halide lithium halide, C 1 -C 6 linear or branched alkyl lithium, metal magnesium, metal zinc, and metal lithium.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011278152.XA CN114507163A (en) | 2020-11-16 | 2020-11-16 | Method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride |
CN202011278152.X | 2020-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022100195A1 true WO2022100195A1 (en) | 2022-05-19 |
Family
ID=81546439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/114067 WO2022100195A1 (en) | 2020-11-16 | 2021-08-23 | Method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114507163A (en) |
WO (1) | WO2022100195A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012407A (en) * | 2011-09-27 | 2013-04-03 | 赛诺菲 | N-[4-(1H-pyrazolo[3,4-b]pyrazine-6-yl)-phenyl]-sulfonamides and application of N-[4-(1H-pyrazolo[3,4-b]pyrazine-6-yl)-phenyl]-sulfonamides as medicines |
CN108003161A (en) * | 2016-10-28 | 2018-05-08 | 正大天晴药业集团股份有限公司 | Neurotrophic factor tyrosine kinase receptor inhibitor |
CN109593803A (en) * | 2018-12-24 | 2019-04-09 | 上海健康医学院 | (R) preparation method of -2- (2,5- difluorophenyl) pyrrolidines or its salt |
CN109593802A (en) * | 2018-12-24 | 2019-04-09 | 上海健康医学院 | The preparation method of one kind (R) -2- (2,5- difluorophenyl) pyrrolidines or its salt |
WO2020079205A1 (en) * | 2018-10-19 | 2020-04-23 | Les Laboratoires Servier | New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |
CN111647011A (en) * | 2020-07-16 | 2020-09-11 | 宁夏中星显示材料有限公司 | Preparation method of monohalogenated phenylboronic acid |
-
2020
- 2020-11-16 CN CN202011278152.XA patent/CN114507163A/en active Pending
-
2021
- 2021-08-23 WO PCT/CN2021/114067 patent/WO2022100195A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012407A (en) * | 2011-09-27 | 2013-04-03 | 赛诺菲 | N-[4-(1H-pyrazolo[3,4-b]pyrazine-6-yl)-phenyl]-sulfonamides and application of N-[4-(1H-pyrazolo[3,4-b]pyrazine-6-yl)-phenyl]-sulfonamides as medicines |
CN108003161A (en) * | 2016-10-28 | 2018-05-08 | 正大天晴药业集团股份有限公司 | Neurotrophic factor tyrosine kinase receptor inhibitor |
WO2020079205A1 (en) * | 2018-10-19 | 2020-04-23 | Les Laboratoires Servier | New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |
CN109593803A (en) * | 2018-12-24 | 2019-04-09 | 上海健康医学院 | (R) preparation method of -2- (2,5- difluorophenyl) pyrrolidines or its salt |
CN109593802A (en) * | 2018-12-24 | 2019-04-09 | 上海健康医学院 | The preparation method of one kind (R) -2- (2,5- difluorophenyl) pyrrolidines or its salt |
CN111647011A (en) * | 2020-07-16 | 2020-09-11 | 宁夏中星显示材料有限公司 | Preparation method of monohalogenated phenylboronic acid |
Non-Patent Citations (6)
Title |
---|
BHATTACHARYA S. N., EABORN C., WALTON D. R. M.: "Preparation of arenesulphonyl chlorides from Grignard reagents", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY.>6015C, CHEMICAL SOCIETY. LETCHWORTH., GB, 1 January 1968 (1968-01-01), GB , pages 1265, XP055930352, ISSN: 0022-4952, DOI: 10.1039/j39680001265 * |
DAVIES ALYN T., CURTO JOHN M., BAGLEY SCOTT W., WILLIS MICHAEL C.: "One-pot palladium-catalyzed synthesis of sulfonyl fluorides from aryl bromides", CHEMICAL SCIENCE, ROYAL SOCIETY OF CHEMISTRY, UNITED KINGDOM, vol. 8, no. 2, 1 January 2017 (2017-01-01), United Kingdom , pages 1233 - 1237, XP055930360, ISSN: 2041-6520, DOI: 10.1039/C6SC03924C * |
HAY J. V.: "CHEMISTRY OF SULFONYLUREA HERBICIDES.", PESTICIDE SCIENCE., ELSEVIER APPLIED SCIENCE PUBLISHER. BARKING., GB, vol. 29., no. 03., 1 January 1990 (1990-01-01), GB , pages 247 - 261., XP000202810, ISSN: 0031-613X * |
LEO A. PAQUETTE: "Encyclopedia of reagents for organic synthesis; Vol. 7 : Sod - Trim", WILEY , Chichester , ISBN: 978-0-470-84289-8, article ANILKUMAR R., BURTON DONALD J.: "Chloropentafluorobenzene", XP055930355, DOI: 10.1002/047084289X.rn00539 * |
MICHAEL A. WALLACE, CONRAD E. RAAB, DENNIS C. DEAN, DAVID G. MELILLO: "Synthesis of [35S]aryl sulfonyl chlorides from [35S]elemental sulfur", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, JOHN WILEY & SONS LTD., GB, vol. 48, no. 4, 30 March 2005 (2005-03-30), GB , pages 275 - 283, XP055661462, ISSN: 0362-4803, DOI: 10.1002/jlcr.920 * |
ZEKRI NEGAR; FAREGHI-ALAMDARI REZA; MOMENI-FARD BEHNAZ: "Synthesis of ketamine from a nontoxic procedure: a new and efficient route", JOURNAL OF CHEMICAL SCIENCES, SPRINGER INDIA, NEW DELHI, vol. 132, no. 1, 25 September 2020 (2020-09-25), New Delhi, XP037255628, ISSN: 0974-3626, DOI: 10.1007/s12039-020-01827-9 * |
Also Published As
Publication number | Publication date |
---|---|
CN114507163A (en) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0570594B1 (en) | Hydroxamic acid derivative based on aromatic sulfonamide | |
CA3082115A1 (en) | Process for preparing tapinarof | |
JPH03128343A (en) | Novel zinc derivative of anti-inflammatory drug having improved therapeutic characteristics | |
US3987091A (en) | 11,12-secoprostaglandins | |
US3853952A (en) | 2-ethynylcyclopropane compounds and process for the preparation thereof | |
US3120551A (en) | 5-(4-biphenylyl)-3-methylvaleric acid and functional derivatives thereof | |
US4159279A (en) | Nuclear substituted 2-hydroxyphenylmethanesulfamic acids | |
EP0000200B1 (en) | New n-amidino-3,5-diamino-6-substituted-2-pyrazinecarboxamides and process for preparing same | |
WO2022100195A1 (en) | Method for preparing 2-fluoro-5-methoxybenzenesulfonyl chloride | |
Fieser et al. | The Addition of Dichlorocarbene to cis, cis-1, 5-Cyclooctadiene | |
US4091107A (en) | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins | |
US3873539A (en) | Substituted-4-aminoacetyl alkanoylphenones | |
JPS62123180A (en) | P-aminophenol derivative | |
Henry | The Reaction of Amines with N-Methyl-N-nitroso-N'-nitroguanidine | |
JPH0567142B2 (en) | ||
IE45110B1 (en) | New phenethylamine derivatives and salts thereof,as well as processes for their preparation and pharmaceutical compositions incorporating them | |
FI70711C (en) | PHARMACEUTICAL FORM OF PHARMACOLOGICAL ACTIVE HOEGERVIDIDES ISOMER AV (+) - OZOLINONESTER | |
US4273787A (en) | 1-Alkyl,1-phenyl-butenes | |
US4034045A (en) | 2,4-Disubstituted-4b,5,6,7,8,8a,9,10-octahydro-9-oxo-phenanthrenes | |
US3598861A (en) | 2-(5'-phenyl-m-terphenyl - 4 - yloxy) lower aliphatic monocarbocyclic acids and esters thereof | |
EP0013726B1 (en) | Indanyloxamic derivatives, their preparation and pharmaceutical compositions containing them | |
JPS5857419B2 (en) | Method for producing 1-cyclopropyl-1-phenyl-ω-amino-1-lower alkanoyloxyalkanes | |
US4049825A (en) | Aminoalkylethers; composition and method of use | |
JPS5919537B2 (en) | Oxindole derivative | |
US2293877A (en) | Amino compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21890724 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21890724 Country of ref document: EP Kind code of ref document: A1 |